Bioventus Beats on Margins, Trims Sales Guidance as Strategic Review Continues
BVS has more than doubled off its 52-week low of $6.47.
Summary
Bioventus posted Q3 revenue of $142.4 million, up 2.7% year over year, with net income attributable to the company of $6.0 million versus $3.2 million a year ago. Adjusted EBITDA rose 7% to $28.4 million on a 74.7% non-GAAP gross margin, and non-GAAP EPS of $0.17 beat last year's $0.15. The company also made a $15.0 million discretionary principal prepayment on its term loan, cutting interest expense to $3.8 million from $6.2 million. The blemish is the top line: full-year net sales guidance was trimmed to $590-$595 million (roughly 4-5% growth), while Adjusted EPS guidance of $0.75-$0.79 was reaffirmed. Management said the strategic alternatives review — launched after an unsolicited acquisition proposal — is ongoing, and $3.6 million of related costs hit the quarter.
At the time of this announcement, BVS was trading at $13.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.47 to $15.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.